161 related articles for article (PubMed ID: 32142497)
21. Cyclin D1 and p16 Expression in Blue Nevi and Malignant Melanoma.
Donigan JM; De Luca J; Lum C
Appl Immunohistochem Mol Morphol; 2017 Feb; 25(2):91-94. PubMed ID: 26766120
[TBL] [Abstract][Full Text] [Related]
22. 5-Hydroxymethylcytosine Expression in Proliferative Nodules Arising within Congenital Nevi Allows Differentiation from Malignant Melanoma.
Pavlova O; Fraitag S; Hohl D
J Invest Dermatol; 2016 Dec; 136(12):2453-2461. PubMed ID: 27456754
[TBL] [Abstract][Full Text] [Related]
23. SILAC-based proteomic analysis to dissect the "histone modification signature" of human breast cancer cells.
Cuomo A; Moretti S; Minucci S; Bonaldi T
Amino Acids; 2011 Jul; 41(2):387-99. PubMed ID: 20617350
[TBL] [Abstract][Full Text] [Related]
24. Two distinct modes for propagation of histone PTMs across the cell cycle.
Alabert C; Barth TK; Reverón-Gómez N; Sidoli S; Schmidt A; Jensen ON; Imhof A; Groth A
Genes Dev; 2015 Mar; 29(6):585-90. PubMed ID: 25792596
[TBL] [Abstract][Full Text] [Related]
25. Human monoclonal antibodies that distinguish cutaneous malignant melanomas from benign nevi in fixed tissue sections.
Imam A; Mitchell MS; Modlin RL; Taylor CR; Kempf RA; Kan-Mitchell J
J Invest Dermatol; 1986 Feb; 86(2):145-8. PubMed ID: 3528308
[TBL] [Abstract][Full Text] [Related]
26. DNA-methylation profiling distinguishes malignant melanomas from benign nevi.
Conway K; Edmiston SN; Khondker ZS; Groben PA; Zhou X; Chu H; Kuan PF; Hao H; Carson C; Berwick M; Olilla DW; Thomas NE
Pigment Cell Melanoma Res; 2011 Apr; 24(2):352-60. PubMed ID: 21375697
[TBL] [Abstract][Full Text] [Related]
27. A novel method for isolation of histones from serum and its implications in therapeutics and prognosis of solid tumours.
Reddy D; Khade B; Pandya R; Gupta S
Clin Epigenetics; 2017; 9():30. PubMed ID: 28360947
[TBL] [Abstract][Full Text] [Related]
28. DEK expression in melanocytic lesions.
Kappes F; Khodadoust MS; Yu L; Kim DS; Fullen DR; Markovitz DM; Ma L
Hum Pathol; 2011 Jul; 42(7):932-8. PubMed ID: 21316078
[TBL] [Abstract][Full Text] [Related]
29. Systems Level Analysis of Histone H3 Post-translational Modifications (PTMs) Reveals Features of PTM Crosstalk in Chromatin Regulation.
Schwämmle V; Sidoli S; Ruminowicz C; Wu X; Lee CF; Helin K; Jensen ON
Mol Cell Proteomics; 2016 Aug; 15(8):2715-29. PubMed ID: 27302890
[TBL] [Abstract][Full Text] [Related]
30. Expression of activated Akt in benign nevi, Spitz nevi and melanomas.
Kantrow SM; Boyd AS; Ellis DL; Nanney LB; Richmond A; Shyr Y; Robbins JB
J Cutan Pathol; 2007 Aug; 34(8):593-6. PubMed ID: 17640227
[TBL] [Abstract][Full Text] [Related]
31. Role of Histone H3K27 Trimethylation Loss as a Marker for Malignant Peripheral Nerve Sheath Tumor in Fine-Needle Aspiration and Small Biopsy Specimens.
Mito JK; Qian X; Doyle LA; Hornick JL; Jo VY
Am J Clin Pathol; 2017 Aug; 148(2):179-189. PubMed ID: 28898989
[TBL] [Abstract][Full Text] [Related]
32. Differentiation between Spitz nevi and malignant melanomas by interphase fluorescence in situ hybridization.
Wettengel GV; Draeger J; Kiesewetter F; Schell H; Neubauer S; Gebhart E
Int J Oncol; 1999 Jun; 14(6):1177-83. PubMed ID: 10339676
[TBL] [Abstract][Full Text] [Related]
33. Use of p16 immunohistochemical stain to help differentiate inflamed melanocytic nevi from metastatic melanoma in the setting of immunotherapy.
Adelman M; Lyons AB; Seale L; Friedman BJ
J Am Acad Dermatol; 2020 Apr; 82(4):e117-e119. PubMed ID: 31765681
[No Abstract] [Full Text] [Related]
34. p16 Range of expression in dermal predominant benign epithelioid and spindled nevi and melanoma.
Oaxaca G; Billings SD; Ko JS
J Cutan Pathol; 2020 Sep; 47(9):815-823. PubMed ID: 32330325
[TBL] [Abstract][Full Text] [Related]
35. Methylation Patterns of Lys9 and Lys27 on Histone H3 Correlate with Patient Outcome in Gastric Cancer.
Li Y; Guo D; Sun R; Chen P; Qian Q; Fan H
Dig Dis Sci; 2019 Feb; 64(2):439-446. PubMed ID: 30350241
[TBL] [Abstract][Full Text] [Related]
36. The utility of PRAME staining in identifying malignant transformation of melanocytic nevi.
Lohman ME; Steen AJ; Grekin RC; North JP
J Cutan Pathol; 2021 Jul; 48(7):856-862. PubMed ID: 33433032
[TBL] [Abstract][Full Text] [Related]
37. Melanocytic nevi clinically simulating melanoma.
Makino E; Uchida T; Matsushita Y; Inaoki M; Fujimoto W
J Dermatol; 2007 Jan; 34(1):52-5. PubMed ID: 17204102
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma.
Tron VA; Krajewski S; Klein-Parker H; Li G; Ho VC; Reed JC
Am J Pathol; 1995 Mar; 146(3):643-50. PubMed ID: 7534042
[TBL] [Abstract][Full Text] [Related]
39. α-Methylacyl-coenzyme A racemase (AMACR, p504s) is a marker to distinguish malignant melanomas from dysplastic nevi and melanocytic nevi.
Abbas M; Ploch EM; Wehling J; Schipper E; Janciauskiene S; Kreipe HH; Jonigk D
Tumour Biol; 2014 Dec; 35(12):12015-20. PubMed ID: 25149154
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic utility of dual 5-hydroxymethylcytosine/Melan-A immunohistochemistry in differentiating nodal nevus from metastatic melanoma: An effective first-line test for the workup of sentinel lymph node specimen.
Siref AB; Huynh CAT; Balzer BL; Frishberg DP; Essner R; Shon W
J Cutan Pathol; 2019 Apr; 46(4):261-266. PubMed ID: 30632191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
